Activation of group II metabotropic glutamate receptors inhibits synaptic excitation of the substantia Nigra pars reticulata.

Bradley SR, Marino MJ, Wittmann M, Rouse ST, Awad H, Levey AI, Conn PJ
J Neurosci. 2000 20 (9): 3085-94

PMID: 10777772

Loss of nigrostriatal dopaminergic neurons in Parkinson's disease (PD) leads to increased activity of glutamatergic neurons in the subthalamic nucleus (STN). Recent studies reveal that the resultant increase in STN-induced excitation of basal ganglia output nuclei is responsible for the disabling motor impairment characteristic of PD. On the basis of this, it is possible that any manipulation that reduces activity at excitatory STN synapses onto basal ganglia output nuclei could be useful in the treatment of PD. We now report that group II metabotropic glutamate receptors (mGluRs) are presynaptically localized on STN terminals and that activation of these receptors inhibits excitatory transmission at STN synapses. In agreement with the hypothesis that this could provide a therapeutic benefit in PD, a selective agonist of group II mGluRs induces a dramatic reversal of catalepsy in a rat model of PD. These results raise the exciting possibility that selective agonists of group II mGluRs could provide an entirely new approach to the treatment of PD. These novel therapeutic agents would provide a noninvasive pharmacological treatment that does not involve the manipulation of dopaminergic systems, thus avoiding the problems associated with current therapies.

MeSH Terms (16)

Animals Bridged Bicyclo Compounds Catalepsy Dopamine Antagonists Excitatory Amino Acid Agonists Excitatory Postsynaptic Potentials Glutamic Acid Haloperidol Male Parkinson Disease Rats Rats, Sprague-Dawley Receptors, Metabotropic Glutamate Receptors, Presynaptic Substantia Nigra Subthalamic Nucleus

Connections (1)

This publication is referenced by other Labnodes entities:

Links